Overview


According to FutureWise analysis the market for Anticonvulsants in 2023 is US$ 25.17 billion, and is expected to reach US$ 30.96 billion by 2031 at a CAGR of 2.60%.

Anticonvulsants, also known as antiseizure drugs or antiepileptic drugs, are medicines usually used to control or prevent seizures or a series of seizures. They provide comfort from the occurring symptoms and do not change the duration of epilepsy. Epilepsy is a group of interconnected disorders in the brain's electrical systems that are indicated by a tendency to cause recurrent seizures. Seizures cause changes in movement, sensation, behavior, or awareness, including loss of consciousness and convulsions, which last from a few seconds to a few minutes in most people. Seizures may occur in children and adults. Also, antiseizure medications appear to disrupt the overactive transmission of pain signals transmitted from damaged nerves (neuropathy) or overly sensitized nerves, as in fibromyalgia. Anticonvulsants are also used to treat nerve pain and bipolar disorder.

Anticonvulsants comprise a very large family of drugs and are available in different types. Some of them are Barbiturates, Hydantoins, Benzodiazepines, and others. Barbiturates are a class of sedative-hypnotic drugs that are used as anticonvulsants to manage seizure conditions, to induce anesthesia in surgical processes, as anxiolytics to reduce anxiety, and to manage insomnia. Sedatives are medications that help calm down and relax. Barbiturates improve the effect of a chemical called GABA (gamma-aminobutyric acid), which is the central inhibitory neurotransmitter in the brain, by attaching to its receptor.

FutureWise Market Research has published a report that provides an insightful analysis anticonvulsants market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry.

According to the analysis conducted by FutureWise research analysts, anticonvulsants market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

  • Abbott Laboratories
  • Teva Pharmaceutical Industries Ltd.
  • Johnson & Johnson
  • Novartis AG
  • Pfizer Inc.
  • Valeant Pharmaceuticals International, Inc.
  • Sanofi S.A.
  • UCB Group
  • Shire Plc.
  • GlaxoSmithKline Plc.
  • Cephalon Inc.
  • AstraZeneca Plc.

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent Developments in Anticonvulsants Market:

  • In March 2022, Marinus Pharmaceuticals, Inc., a pharmaceutical firm, announced that they had been granted approval from the FDA for their anticonvulsants, ZTALMY (ganaxolone), for the treatment of seizures related to CDKL5 (cyclin-dependent kinase-like) deficiency disorder (CDD) in patients two years of age and older. CDD is a rare genetic epilepsy characterized by early onset, difficult-to-control seizures, and severe neuro-developmental impairment.

The growing incidence of epilepsy and other seizure disorders is anticipated to drive the anticonvulsants market. With an increasing number of individuals diagnosed with these conditions worldwide, the sustained need for anticonvulsant drugs is rising. This trend is propelled by enhanced diagnostic techniques and increasing awareness, leading to more precise and convenient diagnoses. Additionally, the product approval of anticonvulsants by various government bodies is further propelling the growth of the anticonvulsant market. When regulatory bodies like the FDA in the United States or their counterparts in other countries endorse new or improved anticonvulsant drugs, it ensures healthcare experts and patients of their safety and efficiency. It paves the way for broader accessibility and adoption. This regulatory support boosts confidence in prescribers and consumers, thus allowing increased use and demand for these essential pharmaceuticals. For instance, in June 2021, Zydus Pharmaceuticals, Inc., a pharmaceutical firm, announced that they had received approval from the United States FDA for the anticonvulsant drug Brivaracetam tablets, indicated for treating epilepsy that help to control partial onset seizures. However, the adverse side effects of certain anticonvulsant drugs, such as dizziness, drowsiness, and cognitive impairment, may significantly restrain the market's growth. These adverse effects may potentially hinder patient compliance and commitment to prescribed medicines. Thus hampering the target market over the projection period.

By Drug Class

  • Barbiturates
  • Benzodiazepines
  • Hydantoins
  • Succinimides
  • Others

By Application

  • Epilepsy
  • Migraine
  • Fibromyalgia
  • Neuropathic pain
  • Anxiety
  • Bipolar disorder

By Route of Administration

  • Enteral
  • Parenteral
  • Topical

By Distribution Channel

  • Retail Pharmacy
  • Hospital Pharmacy
  • Online Pharmacy

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered highest share in the market in 2022. Due to factors such as the rising number of neurological disorders, increasing investment by major pharmaceutical companies for R&D, rising collaboration between government and pharmaceutical companies, and growing incidences of epilepsy are expected to drive the target market in the region. In addition, the increasing number of product approvals by regulatory bodies is likely to propel the anticonvulsant market growth over the projection period. For instance, in March 2022, Lupin pharmaceutical company announced that they had been granted approval from the U.S. FDA for its abbreviated new anticonvulsants drug application (ANDA), Vigabatrin for Oral Solution USP (500 mg), indicated for epilepsy.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Anticonvulsants Market By Drug Class, By Application, By Route of Administration, By Distribution Channel and By Region.
  • To cater comprehensive insights on factors such as drivers, restraints, trends, opportunity, and additionally segmental and regional factors impacting market growth.
  • To evaluate current market trends and forecast micro-markets and the overall market projections which are represented in the format of data-sets and ppt.
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa. 
  • To provide information on competitors which includes landscape mapping, technological advancements, R&D spending, news concerning strategic alliances, and new product launches

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Global Anticonvulsants Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Anticonvulsants Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Global Anticonvulsants Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Global Anticonvulsants Market, By Drug Class Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Barbiturates
        2. Benzodiazepines
        3. Hydantoins
        4. Succinimides
        5. Others

  • 8.   Global Anticonvulsants Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Epilepsy
        2. Migraine
        3. Fibromyalgia
        4. Neuropathic pain
        5. Anxiety
        6. Bipolar disorder

  • 9.   Global Anticonvulsants Market, By Route of Administration Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Enteral
        2. Parenteral
        3. Topical

  • 10.   Global Anticonvulsants Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Retail Pharmacy
        2. Hospital Pharmacy
        3. Online Pharmacy

  • 11.   North America Anticonvulsants Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 12.   Latin America Anticonvulsants Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 13.   Europe Anticonvulsants Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 14.   Asia Pacific Anticonvulsants Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 15.   Middle East and Africa Anticonvulsants Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 16.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 17.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Abbott Laboratories
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Teva Pharmaceutical Industries Ltd.
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Johnson & Johnson
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Novartis AG
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Pfizer Inc.
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Valeant Pharmaceuticals International, Inc.
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Sanofi S.A.
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. UCB Group
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Shire Plc.
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. GlaxoSmithKline Plc.
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. Cephalon Inc.
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. AstraZeneca Plc.
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview

  • 18.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 19.   FutureWise SME Key Takeaway Points for Client

Related Market

Hydantoin Anticonvulsants Market

Read More
Partner

Our Clients